Physician profile
Peter Rouvelas
NPI 1245243609
$332,291.11
in general payments reported to CMS, 2019-2025
24 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $16K · 2021: $11K · 2022: $113K · 2023: $66K · 2024: $30K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Consulting Fee: $12K · Food and Beverage: $3,090 · Travel and Lodging: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,408.06 |
| Consulting Fee | $11,835.00 |
| Food and Beverage | $3,090.33 |
| Travel and Lodging | $3,064.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $206,647.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $86,418.71 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $27,008.24 | 2019-2020 | |
| Edwards Lifesciences Corporation | $7,484.30 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,442.80 | 2019-2021 | |
| Amgen INC. | $489.09 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $487.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $396.29 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $392.09 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $373.29 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $234.63 | 2020-2025 | Amvuttra |
| Pfizer INC. | $171.22 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $163.83 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $113.91 | 2019-2025 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $83.85 | 2019-2020 | |
| Biotronik INC. | $48.24 | 2019 | |
| Lilly USA, LLC | $46.67 | 2019-2022 | |
| Horizon Therapeutics Plc | $34.50 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.43 | 2019 | |
| Corcept Therapeutics | $22.16 | 2025 | Korlym |
| Astellas Pharma US INC | $19.44 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.90 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rouvelas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.